APA (7th ed.) Citation

Lavie, D., Kerr, D. A., Avigdor, A., Avivi, I., Belada, D., Abrisqueta, P., . . . Thieblemont, C. (2025). 282 | DURABLE EFFICACY WITH FIXED‐DURATION EPCORITAMAB + POLATUZUMAB, VEDOTIN, RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE (POLA‐R‐CHP) FOR 1L DLBCL (EPCORE NHL‐5). Hematological oncology, 43, 1. https://doi.org/10.1002/hon.70094_282

Chicago Style (17th ed.) Citation

Lavie, D., et al. "282 | DURABLE EFFICACY WITH FIXED‐DURATION EPCORITAMAB + POLATUZUMAB, VEDOTIN, RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE (POLA‐R‐CHP) FOR 1L DLBCL (EPCORE NHL‐5)." Hematological Oncology 43 (2025): 1. https://doi.org/10.1002/hon.70094_282.

MLA (9th ed.) Citation

Lavie, D., et al. "282 | DURABLE EFFICACY WITH FIXED‐DURATION EPCORITAMAB + POLATUZUMAB, VEDOTIN, RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE (POLA‐R‐CHP) FOR 1L DLBCL (EPCORE NHL‐5)." Hematological Oncology, vol. 43, 2025, p. 1, https://doi.org/10.1002/hon.70094_282.